These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3555827)

  • 1. [Comparison of the effect of methyltestosterone and testosterone undecanoate in substitution therapy of hypogonadism].
    Hána V; Marek J; Mellanová A; Hampl R; Stárka L
    Cas Lek Cesk; 1987 Mar; 126(12):369-73. PubMed ID: 3555827
    [No Abstract]   [Full Text] [Related]  

  • 2. [Testosterone undecanoate for late -onset hypogonadism: an update].
    Fan XB; Huang YF
    Zhonghua Nan Ke Xue; 2010 Jan; 16(1):68-71. PubMed ID: 20180410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
    Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C
    J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone undecanoate--oral therapy for male hypogonadism.
    Drug Ther Bull; 1985 Jan; 23(2):7-8. PubMed ID: 3967582
    [No Abstract]   [Full Text] [Related]  

  • 5. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes.
    Morales A; Johnston B; Heaton JP; Lundie M
    J Urol; 1997 Mar; 157(3):849-54. PubMed ID: 9072584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen levels and sex functions in testosterone-treated hypogonadal men.
    Gooren LJ
    Arch Sex Behav; 1987 Dec; 16(6):463-73. PubMed ID: 3426390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone replacement in older men and women.
    Morley JE
    J Gend Specif Med; 2001; 4(2):49-53. PubMed ID: 11480098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of male hormone on libido in impuberism and hypogonadism at the age of 20 years].
    Gautier D; Le Van F; Fromantin M
    Probl Actuels Endocrinol Nutr; 1977; (21):57-67. PubMed ID: 617231
    [No Abstract]   [Full Text] [Related]  

  • 9. A ten-year safety study of the oral androgen testosterone undecanoate.
    Gooren LJ
    J Androl; 1994; 15(3):212-5. PubMed ID: 7928661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of testosterone undeconoate in male hypogonadism].
    Mies R; Krempl S
    Med Welt; 1980 Apr; 31(17):619-21. PubMed ID: 7421495
    [No Abstract]   [Full Text] [Related]  

  • 11. [The effectiveness of sex hormone replacement therapy in male hypogonadism].
    Butrova SA; Kogan BS
    Probl Endokrinol (Mosk); 1971; 17(5):43-7. PubMed ID: 5148296
    [No Abstract]   [Full Text] [Related]  

  • 12. Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients.
    Luisi M; Franchi F
    J Endocrinol Invest; 1980; 3(3):305-8. PubMed ID: 7000879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pubertal induction in adult males with isolated hypogonadotropic hypogonadism using long-acting intramuscular testosterone undecanoate 1-g depot (Nebido).
    Santhakumar A; Miller M; Quinton R
    Clin Endocrinol (Oxf); 2014 Jan; 80(1):155-7. PubMed ID: 23383861
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of testosterone supplementation on sexual function in hypogonadal men with erectile dysfunction.
    Mulhall JP; Valenzuela R; Aviv N; Parker M
    Urology; 2004 Feb; 63(2):348-52; discussion 352-3. PubMed ID: 14972487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
    Behre HM; Heinemann L; Morales A; Pexman-Fieth C
    Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents.
    Seftel A
    Int J Impot Res; 2007; 19(1):2-24. PubMed ID: 16193074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S; Nieschlag E
    J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
    Yassin AA; Saad F
    Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R; Swinburne J; Orme S
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Basic principles of modern androgenic therapy].
    Ludvik W
    Urologe; 1970 Jan; 9(1):41-3. PubMed ID: 5418835
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.